Arca
Skip to content

CTLA4: Cytotoxic T-lymphocyte protein 4

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Inhibitory receptor acting as a major negative regulator of T-cell responses.

  • Drugs that act on it: 6
  • With a US drug page: 2
  • Type: Protein

Drugs That Act on It

Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page
IpilimumabApprovedCytotoxic T-lymphocyte protein 4 inhibitorInhibitor—
TremelimumabApprovedCytotoxic T-lymphocyte protein 4 inhibitorInhibitor—
Cadonilimab—Cytotoxic T-lymphocyte protein 4 inhibitorInhibitor—
Erfonrilimab—Cytotoxic T-lymphocyte protein 4 inhibitorInhibitor—
Quavonlimab—Cytotoxic T-lymphocyte protein 4 inhibitorInhibitor—
Zalifrelimab—Cytotoxic T-lymphocyte protein 4 inhibitorInhibitor—

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency
0.80
Hashimoto thyroiditis
0.68
Non-small cell lung carcinoma
0.61
Hypothyroidism
0.60

Drugs and mechanisms are from ChEMBL CHEMBL2364164 (CC BY-SA 3.0). Gene name, function (UniProt P16410, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.